Inner Banner
Speaker
Dec 09-11, 2024 Paris, France

International Conference onStem Cells, Regenerative Medicine and Tissue Engineering

Early Bird Registration Date: May 11, 2024
Abstract Submission Opens: Mar 15, 2024
David Greene

David Greene

R3 Stem Cell
USA

Title: The Therapeutic Effect of Mesenchymal Stem Cells in Diabetic Kidney Disease

Abstract:

Diabetes mellitus (DM) often causes chronic kidney damage despite best medical practices. Diabetic kidney disease (DKD) arises from a complex interaction of factors within the kidney and the whole body. Targeting specific disease-causing agents using drugs has not been effective in treating DKD. However, stem cell therapies offer a promising alternative by addressing multiple disease pathways and promoting kidney regeneration. Mesenchymal stem cells (MSCs) offer great promise due to their superior accessibility ratio from adult tissues and remarkable modes of action, such as the production of paracrine anti-inflammatory and cytoprotective substances. This review critically evaluates the development of MSC treatment for DKD as it moves closer to clinical application. Results from animal models suggest that systemic MSC infusion may positively impact DKD progression. However, few registered and completed clinical trials exist, and whether the treatments are effective in humans is still being determined. Significant knowledge gaps and research opportunities exist, including establishing the ideal source, dose, and timing of MSC delivery, better understanding of in vivo mechanisms, and developing quantitative indicators to obtain a more significant therapeutic response. This paper reviews recent literature on using MSCs in preclinical and clinical trials in DKD. Potent biomarkers related to DKD are also highlighted, which may help better understand MSCs’ action in this disease progression.

Biography:

Greene is a residency and fellowship-trained orthopedic surgeon who has shifted completely into business. He started a healthcare internet marketing company, US Lead Network, that helps medical and dental practices acquire patients on the web in a pay-for-performance manner. The company is now using Artificial Intelligence for marketing which is lowering the cost per lead substantially. He has written two books on Healthcare Internet Marketing that are available for purchase on Amazon. He has been featured as a Top 20 Expert Author by Ezines.com, the top article directory site in the world. Out of over 470,000 authors, Greene ranks #15 as an Expert Author and #1 in the Pain Management category. He also started a regenerative medicine company, R3 Stem Cell, that offers marketing, an IRB-approved protocol, and top products for practices nationwide. R3 offers stem cell training courses that are second to none at https://stemcelltrainingcourse.org

David Greene

David Greene

R3 Stem Cell
USA

Title: The Therapeutic Potential of Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure

Abstract:

Diabetes mellitus (DM) often causes chronic kidney damage despite best medical practices. Diabetic kidney disease (DKD) arises from a complex interaction of factors within the kidney and the whole body. Targeting specific disease-causing agents using drugs has not been effective in treating DKD. However, stem cell therapies offer a promising alternative by addressing multiple disease pathways and promoting kidney regeneration. Mesenchymal stem cells (MSCs) offer great promise due to their superior accessibility ratio from adult tissues and remarkable modes of action, such as the production of paracrine anti-inflammatory and cytoprotective substances. This review critically evaluates the development of MSC treatment for DKD as it moves closer to clinical application. Results from animal models suggest that systemic MSC infusion may positively impact DKD progression. However, few registered and completed clinical trials exist, and whether the treatments are effective in humans is still being determined. Significant knowledge gaps and research opportunities exist, including establishing the ideal source, dose, and timing of MSC delivery, better understanding of in vivo mechanisms, and developing quantitative indicators to obtain a more significant therapeutic response. This paper reviews recent literature on using MSCs in preclinical and clinical trials in DKD. Potent biomarkers related to DKD are also highlighted, which may help better understand MSCs’ action in this disease progression.

Biography:

Greene is a residency and fellowship-trained orthopedic surgeon who has shifted completely into business. He started a healthcare internet marketing company, US Lead Network, that helps medical and dental practices acquire patients on the web in a pay-for-performance manner. The company is now using Artificial Intelligence for marketing which is lowering the cost per lead substantially. He has written two books on Healthcare Internet Marketing that are available for purchase on Amazon. He has been featured as a Top 20 Expert Author by Ezines.com, the top article directory site in the world. Out of over 470,000 authors, Greene ranks #15 as an Expert Author and #1 in the Pain Management category. He also started a regenerative medicine company, R3 Stem Cell, that offers marketing, an IRB-approved protocol, and top products for practices nationwide. R3 offers stem cell training courses that are second to none at https://stemcelltrainingcourse.org

Address

SciconX, Kings Houxse,
17 Soho Square London W1D 3QJ,
United Kingdom


WhatsApp

+44 330 808 1939


Email

stemcells@sciconxevents.com

support@sciconx.com